First National Trust’s Axsome Therapeutics AXSM Stock Holding History

First National Trust’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,412	Closed	-$238K	–	380
2023 Q3	$238K	Hold	3,412	–	–	0.01%	339
2023 Q2	$245K	Sell	3,412 -1,000	-23%	-$73.8K	0.01%	336
2023 Q1	$272K	Sell	4,412 -2,900	-40%	-$191K	0.01%	327
2022 Q4	$564K	Hold	7,312	–	–	0.03%	247
2022 Q3	$326K	Hold	7,312	–	–	0.02%	292
2022 Q2	$280K	Hold	7,312	–	–	0.02%	310
2022 Q1	$303K	Hold	7,312	–	–	0.02%	321
2021 Q4	$276K	Hold	7,312	–	–	0.01%	330
2021 Q3	$241K	Hold	7,312	–	–	0.01%	325
2021 Q2	$493K	Hold	7,312	–	–	0.03%	262
2021 Q1	$414K	Buy	+7,312	New	+$514K	0.03%	271

Other funds holding AXSM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First National Trust's AXSM Position: Q4 2023 in Review

First National Trust sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 3,412 shares — an estimated $238K sold.

First National Trust first reported a position in AXSM in Q1 2021 and held it in 11 quarters. The position peaked at $564K in Q4 2022. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

First National Trust reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
First National Trust sold 3,412 Axsome Therapeutics shares in Q4 2023, an estimated $238K.
First National Trust first reported a position in Axsome Therapeutics in Q1 2021 and held it in 11 quarters.
First National Trust's Axsome Therapeutics position peaked at $564K in Q4 2022.
244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on First National Trust's 13F filing for Q4 2023, filed 6 Feb 2024.